Trabectedin Combined With Durvalumab in Patients With Advanced Pretreated Soft-tissue Sarcomas and Ovarian Carcinomas. (TRAMUNE) .

El Fármaco Nivolumab ( Opdivo ) inhibe ciertas Moleculas lo que permite que el sistema Inmune ataque al Cáncer .

Estamos hablando de Inmunoterapia y del Inicio de Fase I con la combinacion de Yondelis y Nivolumab .

This study is currently recruiting participants. 

Verified May 2017 by Institut Bergonié

Sponsor:

Institut Bergonié

Collaborators:

AstraZeneca

PharmaMar

Information provided by (Responsible Party):

Institut Bergonié

ClinicalTrials.gov Identifier:

NCT03085225 .

Last updated: May 12, 2017.

Last verified: May 2017